Tikomed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi modal mechanism of action, Tikomed's platform rebalances the body’s inflammatory and immune response to acute and chronic inflammation. Currently applied in neurodegeneration and advanced therapies, with an initial focus on ALS, TBI and islet cell transplantation, Tikomed’s highly scalable proprietary technology aims to provide safe, qualitative and affordable medicine to as many patients as possible across the globe. Tikomed is privately-owned and based in Viken, Sweden.